Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy

Open access
Suckau, Lennart, Fechner, Henry, Chemaly, Elie, Krohn, Stefanie, Hadri, Lahouaria, Kockskämper, Jens, Westermann, Dirk, Bisping, Egbert, Ly, Hung, Wang, Xiaomin, Kawase, Yoshiaki, Chen, Jiqiu, Liang, Lifan, Sipo, Isaac, Vetter, Roland, Weger, Stefan, Kurreck, Jens, Erdmann, Volker, Tschope, Carsten, Pieske, Burkert, Lebeche, Djamel, Schultheiss, Heinz-Peter, Hajjar, Roger J., Poller, Wolfgang C. · 2009 · Circulation

Abstract

Background— RNA interference (RNAi) has the potential to be a novel therapeutic strategy in diverse areas of medicine. Here, we report on targeted RNAi for the treatment of heart failure, an important disorder in humans that results from multiple causes. Successful treatment of heart failure is demonstrated in a rat model of transaortic banding by RNAi targeting of phospholamban, a key regulator of cardiac Ca 2+ homeostasis. Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy uses regulatory RNAs to achieve its effect. Methods and Results— We describe structural requirements to obtain high RNAi activity from adenoviral and adeno-associated virus (AAV9) vectors and show that an adenoviral short hairpin RNA vector (AdV-shRNA) silenced phospholamban in cardiomyocytes (primary neonatal rat cardiomyocytes) and improved hemodynamics in heart-failure rats 1 month after aortic root injection. For simplified long-term therapy, we developed a dimeric cardiotropic adeno-associated virus vector (rAAV9-shPLB) to deliver RNAi activity to the heart via intravenous injection. Cardiac phospholamban protein was reduced to 25%, and suppression of sacroplasmic reticulum Ca 2+ ATPase in the HF groups was rescued. In contrast to traditional vectors, rAAV9 showed high affinity for myocardium but low affinity for liver and other organs. rAAV9-shPLB therapy restored diastolic (left ventricular end-diastolic pressure, dp/dt min , and τ) and systolic (fractional shortening) functional parameters to normal ranges. The massive cardiac dilation was normalized, and cardiac hypertrophy, cardiomyocyte diameter, and cardiac fibrosis were reduced significantly. Importantly, no evidence was found of microRNA deregulation or hepatotoxicity during these RNAi therapies. Conclusions— Our data show for the first time the high efficacy of an RNAi therapeutic strategy in a cardiac disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.108.783852

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 212

Metadata

Authors
Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskämper, J., Westermann, D., Bisping, E., Ly, H., Wang, X., Kawase, Y., Chen, J., Liang, L., Sipo, I., Vetter, R., Weger, S., Kurreck, J., Erdmann, V., Tschope, C., Pieske, B., Lebeche, D., Schultheiss, H.-P., Hajjar, R. J., & Poller, W. C.
Venue
Circulation
Published
2009-03-10
Volume
119
Issue
9
Pages
1241-1252
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2089055579
Cited by
212
References
4
FWCI
9.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. https://app.cochat.ai/papers/10.1161/circulationaha.108.783852
The paper
Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskämper, J., Westermann, D., Bisping, E., Ly, H., Wang, X., Kawase, Y., Chen, J., Liang, L., Sipo, I., Vetter, R., Weger, S., Kurreck, J., Erdmann, V., Tschope, C., . . . Poller, W. C. (2009). Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy. Circulation. https://doi.org/10.1161/circulationaha.108.783852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.